The Department of Chemicals and Fertilisers has invited applications for setting up manufacturing facilities for Vitamin B1 under the revised category ‘Other Chemical Synthesis based KSMs/ Drug Intermediaries/ APIs’.
The government decided to change the classification of Vitamin B1 to chemical synthesis route following representations that it can be manufactured through this route.
The classification of ‘Vitamin B1’ has since been changed to ‘Other Chemical Synthesis based KSMs/ Drug Intermediaries/ APIs’.
Accordingly, the rate of incentive has also been revised to 10 per cent for FY 2023-24 to FY 2027-28 instead of earlier rate of 20 per cent for FY 2023-24 to FY 2026-27, 15 per cent for FY 2027-28 and 5 per cent for FY 2028-29.
The last date of filing of application has been fixed as 24 August 2022.
The PLI scheme for domestic manufacturing of critical Key Starting Materials (KSMs)/Drug Intermediates and Active Pharmaceuticals Ingredients (APIs) was notified on 20 July 2020.
Financial incentive under the sub-scheme is provided on the sales of 41 identified products categorised into four target segments.
The government received a total of 248 applications in Round I, II and III. Of these, 51 applicants have been approved with committed investment of Rs4,138.41 crore, and expected employment generation of around 10,000 persons.
The applicants have committed total production of 92,130 tonnes against the envisioned capacity of 44,610 tonnes for the 34 products approved under the scheme. The production year and incentive year for chemical synthesis route for Bulk Drugs is from 2022-23 and the production year and incentive year for the fermentation based APIs is from 2023-24. Fourteen projects have been commissioned till the end of June.
Under the scheme guidelines, the eligible product, ‘Vitamin B1,’ was categorised under the head ‘Fermentation based niche KSMs/ Drug Intermediaries/ APIs’ and applications were invited accordingly.